Medicxi
Medicxi is a life sciences-focused investment firm.
Business Model:
Revenue: $1M
Employees: 11-50
Rankings
Industries / Tags:
Detailed Medicxi Information
Geographic Data
Address: 25 Great Pulteney Street
City: London
State: england
Zip: W1F 9LT
Country: GB
Financial Info
Stage:
Raised Last:
$0
Raised Total:$1B
Social
Twitter
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Medicxi is an international investment firm focused on the life sciences sector. It was established in 2016 by the former Index Ventures life sciences team, who have been active for over 20 years and have significant experience in drug discovery and the development of therapeutics for unmet medical needs.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 10/2016 | Mavalon Therapeutics | Seed Round | 0 |
| 6/2018 | Vaxcyte | Series C | 85M |
| 2/2017 | SuperX | Series A | 11M |
| 1/2020 | Alderaan Biotechnology | Series A | 20.6M |
| 12/2014 | Stealthyx Therapeutics | Seed Round | 3.1M |
| 5/2018 | Xenikos | Series B | 30M |
| 6/2022 | MiroBio | Series B | 0 |
| 11/2022 | New Amsterdam Pharma | Post-IPO Equity | 0 |
| 8/2021 | Sydnexis | Series B | 0 |
| 3/2020 | Vaxcyte | Series D | 0 |
| 5/2017 | Z Factor | Series A | 9M |
| 9/2022 | Rivus Pharmaceuticals | Series B | 132M |
| 6/2020 | Checkmate Pharmaceuticals | Series C | 85M |
| 6/2021 | Kurome Therapeutics | Series A | 0 |
| 8/2021 | Versanis Bio | Series A | 0 |
| 10/2016 | Kymo Therapeutics | Seed Round | 11M |
| 9/2021 | Xenikos | Convertible Note | 47.3M |
| 3/2021 | Aura Biosciences | Venture Round | 0 |
| 4/2019 | Aura Biosciences | Series D | 40M |
| 1/2020 | Vaderis Therapeutics | Series A | 18.6M |
| 5/2017 | Palladio Biosciences | Series A | - |
| 7/2019 | Breakpoint Therapeutics | Venture Round | 33.6M |
| 9/2020 | Palladio Biosciences | Series B | 20M |
| 10/2017 | Sydnexis | Venture Round | 5.5M |
| 3/2016 | Gadeta | Series A | 7.9M |
| 11/2017 | Critical Pressure | Series A | 13.2M |
| 9/2019 | Divide and Conquer | Series A | 12.4M |
| 12/2018 | Morphogen-IX | Series B | 23.3M |
| 2/2019 | Inexia | Seed Round | - |
| 10/2017 | Impact Biomedicines | Series A | 22M |
| 7/2021 | Rivus Pharmaceuticals | Series A | 35M |
| 7/2017 | Diasome Pharmaceuticals | Venture Round | 0 |
| 5/2019 | Phathom Pharmaceuticals | Private Equity Round | 90M |
| 3/2016 | Capella BioScience | Series A | 15.5M |
| 4/2018 | Synthorx | Series C | 63M |
| 10/2017 | Janpix | Series A | 17.7M |
| 2/2019 | Orexia | Seed Round | - |
| 6/2019 | Yukin Therapeutics | Venture Round | 3.7M |
| 2/2017 | ApcinteX | Series A | 17.5M |
| 10/2020 | Janpix | Series B | 10M |
| 6/2022 | MiroBio | Series B | 0 |
| 9/2021 | Xenikos | Convertible Note | 0 |
| 8/2021 | Versanis Bio | Series A | 0 |
| 8/2021 | Sydnexis | Series B | 0 |
| 7/2021 | Rivus Pharmaceuticals | Series A | 0 |
| 6/2021 | Kurome Therapeutics | Series A | 0 |
| 3/2021 | Aura Biosciences | Venture Round | 0 |
| 10/2020 | Janpix | Series B | 0 |
| 9/2020 | Palladio Biosciences | Series B | 0 |
| 6/2020 | Checkmate Pharmaceuticals | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
